These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 10876765

  • 1. [Role of mutations in the A-subunit of Acholeplasma laidlawii PG-8B topoisomerase IV in formation of resistance to fluoroquinolones].
    Taganov KD, Gushchin AE, Abramycheva NIu, Govorun VM.
    Mol Gen Mikrobiol Virusol; 2000; (2):30-3. PubMed ID: 10876765
    [Abstract] [Full Text] [Related]

  • 2. [Formation of M. hominis and A. laidlawii resistance to fluoroquinolones].
    Govorun VM, Gushchin AE, Ladygina VG, Abramycheva NIu, Topol' IuIu.
    Mol Gen Mikrobiol Virusol; 1998; (3):16-9. PubMed ID: 9819821
    [Abstract] [Full Text] [Related]

  • 3. [Role of mutations in parC and gyrA in forming resistance of Mycoplasma hominis to fluoroquinolones].
    Gushchin AE, Ladygina VG, Govorun VM.
    Mol Gen Mikrobiol Virusol; 1999; (4):19-24. PubMed ID: 10621934
    [Abstract] [Full Text] [Related]

  • 4. [Analysis of regions determining resistence to fluoroquinolones in genes gyrA and parC in clinical isolates of Mycoplasma hominis].
    Gushchin AE, Ladygina VG, Govorun VM, Taraskina AM, Savicheva AM.
    Mol Gen Mikrobiol Virusol; 2000; (4):33-5. PubMed ID: 11186458
    [Abstract] [Full Text] [Related]

  • 5. Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance.
    Pan XS, Fisher LM.
    J Bacteriol; 1996 Jul; 178(14):4060-9. PubMed ID: 8763932
    [Abstract] [Full Text] [Related]

  • 6. Characterization of a point mutation in the parC gene of Mycoplasma bovirhinis associated with fluoroquinolone resistance.
    Hirose K, Kawasaki Y, Kotani K, Abiko K, Sato H.
    J Vet Med B Infect Dis Vet Public Health; 2004 May; 51(4):169-75. PubMed ID: 15228551
    [Abstract] [Full Text] [Related]

  • 7. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones.
    Ferrero L, Cameron B, Manse B, Lagneaux D, Crouzet J, Famechon A, Blanche F.
    Mol Microbiol; 1994 Aug; 13(4):641-53. PubMed ID: 7997176
    [Abstract] [Full Text] [Related]

  • 8. Correlation of in vitro susceptibilities to newer quinolones of naturally occurring quinolone-resistant Neisseria gonorrhoeae strains with changes in GyrA and ParC.
    Shultz TR, Tapsall JW, White PA.
    Antimicrob Agents Chemother; 2001 Mar; 45(3):734-8. PubMed ID: 11181352
    [Abstract] [Full Text] [Related]

  • 9. In vitro exchange of fluoroquinolone resistance determinants between Streptococcus pneumoniae and viridans streptococci and genomic organization of the parE-parC region in S. mitis.
    Janoir C, Podglajen I, Kitzis MD, Poyart C, Gutmann L.
    J Infect Dis; 1999 Aug; 180(2):555-8. PubMed ID: 10395882
    [Abstract] [Full Text] [Related]

  • 10. Comparison of full gyrA, gyrB, parC and parE gene sequences between all Ureaplasma parvum and Ureaplasma urealyticum serovars to separate true fluoroquinolone antibiotic resistance mutations from non-resistance polymorphism.
    Beeton ML, Chalker VJ, Kotecha S, Spiller OB.
    J Antimicrob Chemother; 2009 Sep; 64(3):529-38. PubMed ID: 19567408
    [Abstract] [Full Text] [Related]

  • 11. Fluoroquinolone resistance and gyrA and parC mutations of Escherichia coli isolated from chicken.
    Lee YJ, Cho JK, Kim KS, Tak RB, Kim AR, Kim JW, Im SK, Kim BH.
    J Microbiol; 2005 Oct; 43(5):391-7. PubMed ID: 16273029
    [Abstract] [Full Text] [Related]

  • 12. Alterations in the GyrA and GyrB subunits of topoisomerase II and the ParC and ParE subunits of topoisomerase IV in ciprofloxacin-resistant clinical isolates of Pseudomonas aeruginosa.
    Lee JK, Lee YS, Park YK, Kim BS.
    Int J Antimicrob Agents; 2005 Apr; 25(4):290-5. PubMed ID: 15784307
    [Abstract] [Full Text] [Related]

  • 13. [Analysis of point mutations in the ygeD, gyrA and parC genes in fluoroquinolones resistant clinical isolates of Chlamydia trachomatis].
    Misiurina OIu, Shipitsina EV, Finashutina IuP, Lazarev VN, Akopian TA, Savicheva AM, Govorun VM.
    Mol Gen Mikrobiol Virusol; 2004 Apr; (3):3-7. PubMed ID: 15354934
    [Abstract] [Full Text] [Related]

  • 14. DNA gyrase-mediated natural resistance to fluoroquinolones in Ehrlichia spp.
    Maurin M, Abergel C, Raoult D.
    Antimicrob Agents Chemother; 2001 Jul; 45(7):2098-105. PubMed ID: 11408229
    [Abstract] [Full Text] [Related]

  • 15. [Susceptibility of 570 Pseudomonas aeruginosa strains to 11 antimicrobial agents and the mechanism of its resistance to fluoroquinolones].
    Lei YC, Wang HB, Sun ZY, Shen ZY.
    Zhonghua Yi Xue Za Zhi; 2003 Mar 10; 83(5):403-7. PubMed ID: 12820918
    [Abstract] [Full Text] [Related]

  • 16. [Analysis of genes, coding for DNA gyrase from the mycoplasma Acholeplasma laidlawii PG-8B].
    Taganov KD, Gushchin AE, Akopian TA, Oparina NIu, Abramycheva NIu, Govorun VM.
    Mol Biol (Mosk); 2000 Mar 10; 34(2):292-9. PubMed ID: 10779957
    [No Abstract] [Full Text] [Related]

  • 17. ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype.
    Muñoz R, De La Campa AG.
    Antimicrob Agents Chemother; 1996 Oct 10; 40(10):2252-7. PubMed ID: 8891124
    [Abstract] [Full Text] [Related]

  • 18. Molecular basis of high-level ciprofloxacin resistance in Neisseria gonorrhoeae strains isolated in Denmark from 1995 to 1998.
    Su X, Lind I.
    Antimicrob Agents Chemother; 2001 Jan 10; 45(1):117-23. PubMed ID: 11120953
    [Abstract] [Full Text] [Related]

  • 19. Resistance of different Chlamydia-like organisms to quinolones and mutations in the quinoline resistance-determining region of the DNA gyrase A- and topoisomerase-encoding genes.
    Casson N, Greub G.
    Int J Antimicrob Agents; 2006 Jun 10; 27(6):541-4. PubMed ID: 16697560
    [Abstract] [Full Text] [Related]

  • 20. Detection of mutations in parC in quinolone-resistant clinical isolates of Escherichia coli.
    Vila J, Ruiz J, Goñi P, De Anta MT.
    Antimicrob Agents Chemother; 1996 Feb 10; 40(2):491-3. PubMed ID: 8834907
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.